MedTrace Logo

Biomarker Rule in/Out in Patients With Acute Diseases for Validation of AKI (BRAVA) Acute Kidney Injury

NCT03754023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 818

Last updated 2021-03-09

No results posted yet for this study

Summary

The presence or development of AKI impacts on outcomes in patients presenting with acute conditions to the ED. As a result, treating physicians are often concerned with the risk of AKI and take such risk in consideration when making subsequent therapeutic and diagnostic decisions which may result in delaying or withholding therapeutic measures in order to prevent further kidney damage (i.e. avoid imaging studies with contrast media).

If clinicians could be informed early that a patient is at minimal risk for AKI, they could deploy timely and optimal diagnostic and treatment procedures for the underlying disease of the patient without major concerns for causing or exacerbating kidney damage

Conditions

Interventions

DIAGNOSTIC_TEST

Urine-TIMP-IGFBP7 biomarker for AKI

Urine-TIMP-IGFBP7 biomarker for AKI

Sponsors & Collaborators

  • GREAT Network Italy

    lead NETWORK

Principal Investigators

  • Salvatore Di Somma · GREAT Network Italy

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-06-30
Completion
2019-11-30
FDA Device
Yes

Countries

  • Australia
  • India
  • Singapore
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03754023 on ClinicalTrials.gov